Antigen binding molecules specific for an anti-CD19 scFV

Patent metadata

Field	Value
Publication number	US-12202909-B2
Application number	US-202217836862-A
Country	US
Kind code	B2
Filing date	Jun 9, 2022
Priority date	Sep 28, 2016
Publication date	Jan 21, 2025
Grant date	Jan 21, 2025

Abstract

Isolated antigen binding molecules that specifically bind to an anti-CD19 scFv comprising SEQ ID NO: 1 are provided. The antigen binding molecules can be used in the methods provided herein.

First claim

What is claimed is:

1. An isolated antigen binding molecule that specifically binds a molecule comprising SEQ ID NO: 1, wherein the antigen binding molecule comprises:
(a) a heavy chain variable region (VH) complementary determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 41;
(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 42;
(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 43;
(d) a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 47;
(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 48; and
(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 49.

2. The antigen binding molecule of claim 1 , wherein the antigen binding molecule is selected from the group consisting of an antibody, an scFv, a Fab, a Fab′, a Fv, a F(ab′) 2, a rabbit antibody, a mouse antibody, a rat antibody, a non-human primate antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an IgE antibody, an IgD antibody, an IgM antibody, an IgG1 antibody, an IgG1 antibody having at least one mutation in the hinge region, an IgG2 antibody, an IgG2 antibody having at least one mutation in the hinge region, an IgG3 antibody, an IgG3 antibody having at least one mutation in the hinge region, an IgG4 antibody, an IgG4 antibody having at least one mutation in the hinge region, an antibody comprising at least one non-naturally occurring amino acid, and any combination thereof.

3. The antigen binding molecule of claim 1 , wherein the antigen binding molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 40.

4. The antigen binding molecule of claim 1 , wherein the antigen binding molecule comprises a VL comprising the amino acid sequence of SEQ ID NO: 46.

5. The antigen binding molecule of claim 1 , wherein the antigen binding molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 40 and a VL comprising the amino acid sequence of SEQ ID NO: 46.

6. The antigen binding molecule of claim 1 , wherein the antigen binding molecule further comprises a detectable label.

7. The antigen binding molecule of claim 6 , wherein the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.

8. The antigen binding molecule of claim 7 , wherein the fluorescent label is selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean, mCFP, mTurquoise2, ECFP, CyPet, GFP (Y66W mutation), mKeima-Red, TagCFP, AmCyan1, mTFP1, GFP (S65A mutation), Midorishi Cyan, Wild Type GFP, GFP (S65C mutation), TurboGFP, TagGFP, GFP (S65L mutation), Emerald, GFP (S65T mutation), EGFP, Azami Green, ZsGreen1, TagYFP, EYFP, Topaz, Venus, mCitrine, YPet, Turbo YFP, ZsYellow1, Kusabira Orange, mOrange, mKO, TurboRFP, tdTomato, TagRFP, DsRed monomer, DsRed2 (“RFP”), mStrawberry, TurboFP602, AsRed2, mRFP1, J-Red, B-phycoeryhring (BPE), mCherry, HcRed1, Katusha, P3, Peridinin Chlorophyll (PerCP), mKate (TagFP635), TurboFP635, mPlum, and mRaspberry.

9. A composition comprising the antigen binding molecule of claim 1 .

Assignees

• Kite Pharma Inc

Inventors

• SIEVERS Stuart
• Wiltzius Jed

Classifications

• G01N33/686

  Anti-idiotype · CPC title

• G01N33/56972

  White blood cells · CPC title

• C07K2319/74

  containing a fusion for binding to a cell surface receptor · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title